Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Prusogliptin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Prusogliptin is a once-a-day tablet for type 2 diabetes, developed in China by CSPC Pharmaceutical Group, where it is sold as 善泽平® (Shanzeping). It helps the body release insulin when blood sugar rises and keeps the sugar-raising hormone glucagon in check.
China's National Medical Products Administration (NMPA) approved it in January 2025 as a Class 1 new chemical drug, to improve blood sugar control in adults with type 2 diabetes:
It is a prescription diabetes and hormone medicine and should be used under an endocrinologist, diabetologist or physician.
Prusogliptin is a highly selective DPP-4 inhibitor. DPP-4 is an enzyme that quickly breaks down GLP-1, a gut hormone released after eating. By blocking the enzyme, prusogliptin keeps more active GLP-1 in the blood. This makes the pancreas more responsive to sugar: it releases more insulin when glucose is high and less glucagon, so blood sugar comes down.
The approval was based on two phase 3 trials, one with prusogliptin on its own and one with metformin. The add-on trial, published in Diabetes, Obesity and Metabolism in 2022, included 214 adults in China whose diabetes was not controlled on metformin. After 24 weeks, HbA1c fell by 0.70% with prusogliptin plus metformin against 0.07% with placebo plus metformin, a difference of 0.63%. Half of the patients on prusogliptin (50.0%) reached an HbA1c of 7.0% or lower, compared with 21.1% on placebo, and after-meal sugar dropped by 2.43 mmol/L against 0.70 mmol/L.
Your doctor will confirm the dose and how it fits with your other diabetes medicines.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Only for type 2 diabetes: it is approved to improve blood sugar control in type 2 diabetes. It is not a treatment for type 1 diabetes or diabetic ketoacidosis.
Overall: in the 24-week add-on trial, side effects judged to be related to treatment occurred in 8.5% of people on prusogliptin and 11.3% on placebo. Serious side effects affected 4.2% against 5.6%, and only 1.4% in each group stopped because of side effects. Body weight did not change meaningfully. Safety in pregnancy, breastfeeding and children has not been established in the published data. Your doctor should read the full Chinese prescribing information for the complete warnings.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box holds 7 tablets of 100 mg, which is one week of treatment at one tablet a day, so a month needs four to five boxes. The label says to keep the tablets sealed and below 30°C, and they travel in their original packs under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.
Patients in Delhi benefit from being close to our New Delhi dispatch point, so each repeat supply can reach them quickly.
Diabetologists in Mumbai can request the tablets for a named patient and plan several weeks of supply at a time.
Once the documents are checked, patients in Bangalore can have the boxes delivered to their home or clinic.
Doctors in Chennai can share the prescription and blood sugar reports with us to begin the import.
We set up repeat orders for patients in Hyderabad so daily treatment carries on without interruption.
For Kolkata and the eastern states, deliveries are timed so the next supply arrives before the last box is finished.
Patients in Pune can use the same documented import route, with updates at each stage.
Physicians in Ahmedabad can coordinate access for patients whose doctor has chosen this specific medicine.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating clinic.
Patients in Rajasthan can receive their tablets at home, provided the import is in their own name.
We arrange delivery for patients under the care of diabetes clinics across Uttar Pradesh.
Patients in Kochi and across Kerala can have regular supplies delivered close to home.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
